Relatlimab plus nivolumab confers benefit across key subgroups in advanced melanoma
Source: Helio, June 2022
CHICAGO —Adding relatlimab to nivolumab improved PFS, OS and objective response rates across key subgroups of patients with previously untreated metastatic or unresectable melanoma, according to a study presented at ASCO Annual Meeting.
The results showed superiority of nivolumab and relatlimab-rmbw (Opdualag, Bristol Myers Squibb) over single-agent nivolumab (Opdivo, Bristol Myers Squibb), consistent with findings among the overall population in the randomized phase 2/3 RELATIVITY-047 trial, Hussein A. Tawbi, MD, PhD, co-director of the Brain
Metastasis Clinic at The University of Texas MD Anderson Cancer Center, told Healio.
The combination also exhibited a favorable risk-benefit profile.